Sage Group News

SAJE Pharma - An Opportunity to Access A Unique and Powerful Multi-Drug Discovery Platform Focused o

SAJE Pharma (www.sajepharma.com) seeks an acquirer or licensee of its GSNORi (S-nitrosoglutathione reductase inhibitor) drug discovery platform. This is a novel approach based on regulating the nitrosylation signal transduction pathways which will lead to multiple drug candidates to treat many major-market diseases driven by inflammation, oxidant damage, and fibrosis. SAJE’s platform is based on its proprietary knowledge of the Structure Activity Relationship (SAR) of the GSNOR enzyme from which it has developed a growing drug library, has demonstrated pre-clinical efficacy and early safety, and with Foley and Lardner has filed composition of matter and use patents on the basis of the platfo